<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Nelfinavir: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i842.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i842.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i842.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i391.htm">Antivirals</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i922.htm" title="Previous: Lopinavir">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i843.htm" title="Next: Nevirapine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i842">Nelfinavir</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Nelfinavir</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i30.htm">Alfuzosin</a></td><td>manufacturer of  nelfinavir advises avoid concomitant use with alfuzosin </td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  nelfinavir given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i1217.htm" name="_1217">Apixaban</a></td><td>avoidance of  nelfinavir advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1011.htm" name="_1011">Aripiprazole</a></td><td class="cBV"><b> nelfinavir possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i937.htm" name="_937">Artemether with Lumefantrine</a></td><td>caution with  nelfinavir advised by manufacturer of artemether/lumefantrine </td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  nelfinavir given with atorvastatin </td><td></td></tr><tr><td><a href="41001i167.htm" name="_167">Azithromycin</a></td><td> nelfinavir increases plasma concentration of azithromycin (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i496.htm" name="_496">Budesonide</a></td><td> nelfinavir possibly increases plasma concentration of budesonide (including <i>inhaled</i> and <i>intranasal</i> budesonide)</td><td></td></tr><tr><td><a href="41001i1204.htm" name="_1204">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  nelfinavir advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  nelfinavir possibly reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i499.htm" name="_499">Ciclosporin</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of ciclosporin </b></td><td></td></tr><tr><td><a href="41001i483.htm" name="_483">Colchicine</a></td><td class="cBV"><b> nelfinavir possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i1076.htm" name="_1076">Darifenacin</a></td><td>avoidance of  nelfinavir advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i963.htm" name="_963">Eletriptan</a></td><td class="cBV"><b> nelfinavir increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm" name="_1025">Eplerenone</a></td><td class="cBV"><b> nelfinavir increases plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  nelfinavir given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i914.htm">Esomeprazole</a></td><td class="cBV"><b>plasma concentration of  nelfinavir possibly reduced by esomeprazole—manufacturer of esomeprazole advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td>plasma concentration of  nelfinavir possibly increased by etravirine—avoid concomitant use</td><td></td></tr><tr><td><a href="41001i1169.htm" name="_1169">Everolimus</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1119.htm" name="_1119">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  nelfinavir given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i497.htm" name="_497">Fluticasone</a></td><td> nelfinavir possibly increases plasma concentration of <i>inhaled</i> and <i>intranasal</i> fluticasone </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td>combination of  nelfinavir with indinavir may increase plasma concentration of either drug (or both)</td><td></td></tr><tr><td><a href="41001i1050.htm" name="_1050">Ivabradine</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of ivabradine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td> nelfinavir reduces plasma concentration of lopinavir , also plasma concentration of active metabolite of nelfinavir increased</td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i1107.htm" name="_1107">Maraviroc</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of maraviroc (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i97.htm" name="_97">Methadone</a></td><td> nelfinavir reduces plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i636.htm" name="_636">Oestrogens</a></td><td class="cBV"><b> nelfinavir accelerates metabolism of oestrogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td class="cBV"><b>plasma concentration of  nelfinavir reduced by omeprazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i517.htm" name="_517">Paclitaxel</a></td><td> nelfinavir increases plasma concentration of paclitaxel </td><td></td></tr><tr><td><a href="41001i1186.htm" name="_1186">Pazopanib</a></td><td class="cBV"><b>avoidance of  nelfinavir advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  nelfinavir possibly reduced by phenobarbital </b></td><td></td></tr><tr><td><a href="41001i284.htm" name="_284">Phenytoin</a></td><td> nelfinavir reduces plasma concentration of phenytoin </td><td></td></tr><tr><td><a href="41001i369.htm" name="_369">Pimozide</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i664.htm" name="_664">Progestogens</a></td><td> nelfinavir possibly reduces contraceptive effect of progestogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i824.htm" name="_824">Quetiapine</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm" name="_341">Quinine</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of quinine (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1147.htm" name="_1147">Ranolazine</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm" name="_200">Rifabutin</a></td><td class="cBV"><b> nelfinavir increases plasma concentration of rifabutin (halve dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  nelfinavir significantly reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>combination of  nelfinavir with ritonavir may increase plasma concentration of either drug (or both)</td><td></td></tr><tr><td><a href="41001i1136.htm" name="_1136">Rivaroxaban</a></td><td>avoidance of  nelfinavir advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i974.htm" name="_974">Rosuvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  nelfinavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i727.htm">Salmeterol</a></td><td>manufacturer of  nelfinavir advises avoid concomitant use with salmeterol </td><td></td></tr><tr><td><a href="41001i791.htm" name="_791">Saquinavir</a></td><td class="cBV"><b> nelfinavir increases plasma concentration of saquinavir—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i858.htm" name="_858">Sildenafil</a></td><td> nelfinavir possibly increases plasma concentration of sildenafil—reduce initial dose of sildenafil</td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  nelfinavir given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1020.htm" name="_1020">Solifenacin</a></td><td> nelfinavir increases plasma concentration of solifenacin </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  nelfinavir reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm" name="_730">Tacrolimus</a></td><td class="cBV"><b> nelfinavir possibly increases plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td>manufacturer of  nelfinavir advises caution with tadalafil </td><td></td></tr><tr><td><a href="41001i946.htm" name="_946">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  nelfinavir in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i850.htm" name="_850">Tolterodine</a></td><td>avoidance of  nelfinavir advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td>manufacturer of  nelfinavir advises caution with vardenafil </td><td></td></tr></tbody></table><p>Nelfinavir belongs to <b>Antivirals</b>
          but <b>Antivirals</b>
          has no interactions information.
        </p></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i922.htm">Previous: Lopinavir</a> | <a class="top" href="41001i842.htm#">Top</a> | <a accesskey="]" href="41001i843.htm">Next: Nevirapine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>